GlassScriptPhysician profile
David G Goldman
NPI 1518047059
$12,370.79
in general payments reported to CMS, 2019-2025
62 companies · $79.78 in 2025
The $79.78 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,397 · 2020: $2,140 · 2021: $4,622 · 2022: $2,030 · 2023: $900 · 2024: $203 · 2025: $79.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $2,500.00 | 2021-2022 | |
| Novo Nordisk INC | $1,078.54 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $759.51 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $733.17 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $650.89 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $639.25 | 2019-2022 | |
| Pfizer INC. | $550.82 | 2019-2023 | |
| Abbvie INC. | $461.76 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $401.34 | 2019-2022 | |
| Amarin Pharma, INC. | $400.07 | 2019-2022 | |
| Abbott Laboratories | $278.60 | 2021-2024 | Freestyle Libre 3, Eterna |
| Teva Pharmaceuticals USA, INC. | $273.40 | 2019-2020 | |
| Smith+Nephew, INC. | $262.06 | 2022-2025 | Grafix Pl, Stravix Pl, Oasis |
| Lilly USA, LLC | $257.19 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.68 | 2019-2021 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.